Jothi  Malar R

Jothi Malar R

Profile ID RP-000-4411 Joined 2023-01-20 3 articles

Articles(3)

Authors: G Lakshmi, Jothi Malar R

DOI: 10.18231/j.ijcbr.2020.061  

Volume7

Issue2

Pages280-284

Abstract

Background: Coronary artery disease (CAD) is a chronic disease and a global health problem, affecting one-third of the world’s population. Recently it has been found that the traditional risk factors of CAD do not account for the total risk. One of the novel risk markers of CAD is Asymmetric dimethylarginine (ADMA), which inhibits the enzyme nitric oxide synthase (NOS), which is required for the synthesis of nitric oxide (NO), a potent vasodilator. Increased ADMA level causes decrease in NO level which will lead to endothelial dysfunction, an underlying causative mechanism for CAD development. ADMA is found to be an independent cardiovascular risk factor. Therefore ADMA may become an additional biochemical parameter to identify those patients who are at higher risk for developing CAD, besides the traditional parameters used. Aim: To study the association between serum ADMA level with coronary artery disease. Materials and Methods: The study design is a case-control study. 80 subjects from the south Indian population between 30 to 60 years of age, of both the sexes were included in the study. Out of them, 40 individuals were angiographically proven cases of CAD from the department of cardiology and 40 healthy individuals from the master health check up department. Various parameters like lipid profile, serum ADMA, blood pressure and BMI were measured in both the groups. The data were collected and analyzed. Result: The ADMA level was found to be significantly elevated in the case group compared with the age matched healthy controls (p value < 0> Conclusion: There is a positive correlation between serum ADMA level and coronary artery disease. Keywords: Asymmetric dimethylarginine(ADMA), Coronary artery disease, Nitric oxide, Endothelial dysfunction, L-Arginine, Nitric oxide synthase.

Open full article page

Authors: Rajeswari Devi V. , Jothi Malar R, Santhi Silambanan, Sungdirenla Jamir

DOI: 10.18231/2394-6377.2018.0066  

Volume5

Issue2

Pages321-323

Abstract

Introduction: Congenital adrenal hyperplasia (CAH) is an adrenal disorder, most commonly caused by 21- hydroxylase enzyme deficiency. Newborn screening for CAH is done by the measurement of 17-hydroxyprogesterone (17-OHP). Aim: To establish the reference limits of 17-OHP in newborns. Materials and Methods: The study was conducted at Sri Ramachandra Medical College and Research Institute (SRMC& RI), Chennai. The clinical data of 360 neonates delivered over a period of two years from January 2015 to December 2016 were retrospectively analyzed. The newborns were grouped according to birth-weight: G1: < 1>2250 g. Based on birth weights 17-OHP cut-off values were determined for each group by rank number. Results: The reference limits for the three group, < 1>2250 g are 2.23 - 59.3, 1.9 - 29.7 and 1.9 - 15.1 nmol/L respectively. The upper reference limits of all the groups are less than the values showed in the kit literature. Conclusion: CAH can be diagnosed by measuring 17-OHP at birth as a part of neonatal screening. Population specific and birth weight specific cut off values of 17-OHP will reduce the false positives. Keywords: Congenital adrenal hyperplasia (CAH), 17-Hydroxyprogesterone (17-OHP), Virilization, Dried blood spot (DBS), Salt-wasting

Open full article page

No matching articles

Try another word from the title, author or DOI.